Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

by rss feed | Sep 10, 2026 | News Feeds

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at...

Nighttime light exposure may alter heart structure and function

by rss feed | Sep 10, 2026 | News Feeds

Exposure to light during the nighttime is linked to important and potentially harmful changes to the structure and function of the heart, according to a study of more than 11,000 people published in the European Heart Journal today (Thursday). Read Original...

Tizanidine looked promising early in a migraine trial, but the benefit did not last

by rss feed | Sep 10, 2026 | News Feeds

A randomized, double-blind, placebo-controlled trial found that low-dose tizanidine did not provide sustained reductions in headache burden over 12 weeks in people with episodic migraine, despite a transient improvement with the 1 mg dose at week 4. Exploratory...

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

by rss feed | Sep 10, 2026 | News Feeds

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg...

Bruker advances whole-organism 3D imaging with enhanced tissue-clearing workflows

by rss feed | Sep 10, 2026 | News Feeds

Bruker Corporation today announced a strategic collaboration with Translucence Biosystems, Inc., a leading provider of tissue‑clearing solutions, to expand its workflow for cleared tissue imaging. Read Original...